Drug Interactions between encorafenib and Libervant

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with encorafenib may significantly reduce the plasma concentrations and effects of drugs that are primarily metabolized by CYP450 3A4, which may lead to decreased efficacy of the concomitant drug(s). Encorafenib is a potent CYP450 3A4 inducer in vivo. Administration of a single 2 mg dose of the sensitive CYP450 3A4 substrate midazolam after repeated administration of encorafenib 450 mg once daily and binimetinib 45 mg twice daily resulted in decreased systemic exposure (AUC) and peak plasma concentration (Cmax) of midazolam by approximately 82% and 74%, respectively, compared to midazolam alone.

MANAGEMENT: Concomitant use of encorafenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids. The prescribing information for the concomitant medication may be consulted to assess the benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of a potent CYP450 3A4 inducer.